BioSpace News Archive

Intensity Therapeutics, Inc. today announced that three abstracts have been selected for presentation at key upcoming clinical oncology conferences.

Ecolab Third Quarter Reported Diluted EPS $1.21; Adjusted Diluted EPS $1.30 With Double-Digit Growth in Sales and Pricing.

Noramco, LLC, a leading North American producer of controlled substance and specialty bulk Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, today announced it has reactivated its previously filed Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for the active pharmaceutical ingredient methylnaltrexone bromide.

Echosens Presents Robust Research at 2022 AASLD Liver Meeting: Noninvasive FibroScan ® Technology Recognized as Critical Component to Optimize Liver Health Management.

Avilar Therapeutics today announced it will present preclinical data demonstrating the degradation of extracellular proteins using its asialoglycoprotein receptor (ASGPR) targeting chimeras (ATAC) platform at the Keystone Symposium on Targeted Protein Degradation being held in Vancouver, British Columbia, November 6-8, 2022.

Ligand Pharmaceuticals Incorporated announced the completion of its expected tax-free distribution of 100% of Ligand’s interest in its subsidiary OmniAb on a pro rata basis to Ligand shareholders of record as of October 26, 2022.

Bausch Health Companies Inc. today announced the presentation of nine posters during the Innovations in Dermatology Conference, which takes place Nov. 3-5, 2022, in Las Vegas, Nev.

Nascent Biotech, Inc. announced today that the United States Patent and Trademark Office will issue patent No. 11,492,394 on November 8, 2022 for claims related to the Company’s lead candidate Pritumumab.

Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives today, reported financial results and business highlights for the third quarter ended September 30, 2022.

Apex Labs Ltd. (“APEX” or the “Company”) is pleased to announce its approval for the first North American take home multi-dose psilocybin clinical trial, APEX-002-A01-02, evaluating the safety and efficacy of APEX-52 (psilocybin) in treating depression in Veterans with Post Traumatic Stress Disorder (“PTSD”).